At the start of the Covid-19 pandemic more than 2 years ago, hopes were high for rapid interventions that could lessen the severity of disease and save lives. Several approved and investigational ...

The study of real-world evidence (RWE) found nearly 9 in 10 patients in a highly vaccinated cohort avoided hospitalization within 15 days of treatment for COVID-19. The study investigators said ...

Although the general population now has at least some immunity against COVID-19, the consequences of severe disease are frequently overlooked for certain patient populations, such as those with ...

Treatment options for mild-to-moderate COVID-19 are becoming increasingly well established. A systematic review and network meta-analysis published in The BMJ evaluated 40 treatments across 187 ...

Please provide your email address to receive an email when new articles are posted on . As the COVID-19 pandemic heads into its 4th year, it is a good time to reflect on strides made for those with ...

The retrospective study evaluated outcomes in patients prescribed nirmatrelvir-ritonavir, as well as the management of drug interactions by clinical pharmacists prescribing the regimen. COVID-19 is ...

Intravenous antiviral remdesivir (Veklury) is now approved for treating COVID patients in an outpatient setting, providing another therapeutic option during the Omicron surge, the FDA announced late ...

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, scientists have worked relentlessly to understand different aspects of the severe acute respiratory syndrome coronavirus 2 ...

In a trial in China involving participants with symptomatic mild-to-moderate Covid-19, VV116 (an oral analogue of remdesivir) was noninferior to nirmatrelvir–ritonavir with respect to the time to ...